Xlife Sciences AG signed a Memorandum of Understanding (MoU) with the regulator of the healthcare sector in the Emirate Abu Dhabi, the Department of Health - Abu Dhabi (DoH). This signed agreement, formalized at the Department's central headquarters, aims to directly enhance patient experiences within the Emirate through a targeted focus on three crucial pillars: empowering and bolstering innovation, utilizing the Xlife Sciences AG working model, and driving forward research and clinical trials. Moreover, this MoU aligns seamlessly with the Department of Health's endeavors to position Abu Dhabi as a worldwide nexus for healthcare and health sciences.

Its effects will be felt on multiple fronts, elevating innovation, enhancing health services, and augmenting treatment options accessible to patients across Abu Dhabi and associated markets. The dynamic partnership between Xlife Sciences AG and the DoH is focused on empowering innovators in the field by offering hands-on incubation training, personalized mentoring, and robust support. The collaboration between Xlife Sciences and DoH creates a funding structure backed by local Abu Dhabi ecosystem partners to drive growth in existing Xlife Sciences AG projects as well as upcoming innovations.

Finally, the collaboration extends its impact to pioneering research and clinical trials, actively propelling forward this vital aspect of healthcare advancement within the UAE. In order to strengthen this MoU, Xlife Sciences AG has joined forces with ICEBERG Capital, a key player based in Abu Dhabi Global Market (ADGM) and regulated by the Financial Services Regulatory Authority (FSRA).